CYP17 gene polymorphisms and prostate cancer risk: A meta‐analysis based on 38 independent studies

Wang, Fang; Zou, Yanfeng; Feng, Xiao-Liang; Su, Hong; Huang, Fen

doi:10.1002/pros.21332

Cited by 33 publications

(33 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous meta-analysis performed by Chen and Pei (2010) showed that the CYP17 T > C polymorphism was not associated with breast cancer risk. However, a recent metaanalysis, which was conducted by Wang et al (2011), suggested that the CYP17 T > C polymorphism is associated with prostate cancer risk in Black population, but not in Caucasian or Asian population. To date, a number of studies have investigated the association between CYP17 gene polymorphism and PCOS risk, and all of them have focused on the T > C polymorphism in the promoter region.…”

Section: Discussionmentioning

confidence: 94%

“…It has been suggested that this change may up-regulate the expression of CYP17, resulting in an increased synthesis of androgens (Carey et al, 1994). The single nucleotide polymorphisms (SNPs) of CYP17 are associated with several diseases including breast cancer, Cushing's syndrome, and prostate cancer in different ethnic groups (Akhtar et al, 2005;Wang et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Polymorphism T→C of gene CYP17 promoter and polycystic ovary syndrome risk: A meta-analysis

Liu

Luo

et al. 2012

Gene

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Polymorphism T→C of gene CYP17 promoter and polycystic ovary syndrome risk: A meta-analysis

Liu

Luo

et al. 2012

Gene

View full text Add to dashboard Cite

“…It is believed that genetic variants are the main risk factors that contribute to prostate cancer. There is now substantial knowledge that many genes and chromosome segments are significantly associated with prostate cancer risks in a multiethnic population, such as PCA3 , CYP17 (Wang et al, 2011), TP53 (Stacey et al, 2011), 8q24 (Zeegers et al, 2011), and 9q22 (Wentzensen et al, 2011). However, no comprehensive knowledge on the precise mechanism of the interaction of these genetic factors, especially in the prognosis of prostate cancer, has been provided to date.…”

Section: Discussionmentioning

confidence: 99%

Effect of IL-18 gene promoter polymorphisms on prostate cancer occurrence and prognosis in Han Chinese population

Liu¹,

Liu²,

Wei³

et al. 2013

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. has been implicated in a wide variety of cellular functions that affect the biological response to tumors. However, there is insufficient evidence to prove that IL-18 gene variants are associated with risk of prostate cancer. We examined a possible association between two promoter polymorphisms, -137G/C (rs187238) and -607C/A (rs1946518), in the IL-18 gene and prostate cancer occurrence and prognosis in Han Chinese. We used a high-resolution melting method to genotype these two polymorphisms in 375 Chinese Han patients with prostate cancer and in 400 age-matched healthy controls. A hundred and eighty-one prostate cancer patients who had been receiving androgen deprivation therapy, including operational and medical castration, were enrolled to follow-up in this study. Carriers of the GG genotype of the -137G/ C polymorphism had a 2.165-times higher risk of prostate cancer progression than carriers of GC [95% confidence interval (CI) = 1.270-3.687]. Patients with the GG genotype at clinical stages III and IV also had significantly lower rates of progression-free survival (relative risk = 2.174, 95%CI = 1.211-3.906). However, we found no significant association of genotype or allele distributions of these two polymorphisms with occurrence of prostate cancer. We conclude that there is evidence that the IL-18 gene promoter polymorphism -137G/ C influences the prognosis of prostate cancer patients in androgen deprivation therapy, although neither of the two SNPs contributes to prostate cancer development.

show abstract

“…Meta-analyses have suggested that variants within CYP17A1 play a role in susceptibility to PCa among African-Americans but not in Caucasian or Asian populations (Ntais et al 2003;Wang et al 2011;Taioli et al 2013;Wang et al 2015). The reasons for the large ethnic differences might be explain by the observation that African-Americans experience earlier puberty, higher serum levels of total testosterone and a higher incidence of PCa (Loukola et al 2004).…”

Section: Cyp17a1 Rs743572 Gene Polymorphismmentioning

confidence: 99%

The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition

Sivoňová

Jurečeková²,

Tatarková³

et al. 2017

gpb

View full text Add to dashboard Cite

Abstract. Androgens play an important role during the development of both normal prostate epithelium and prostate cancer and variants of genes involved in androgen metabolism may be related to an increased risk of prostate disease. Cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1) is a key regulatory enzyme in the steroidogenic pathway; it catalyses both 17α-hydroxylase and 17,20-lyase activities and is essential for the production of both androgens and glucocorticoids. In this review, we focus on the structure and enzymatic activity of CYP17A1 and the mechanism of modulation of CYP17A1 activities. We discuss the relationship between common genetic variations in CYP17A1 gene and prostate cancer risk and the main effects of these variations on the prediction of susceptibility and clinical outcomes of prostate cancer patients. The mechanism of action, the efficacy and the clinical potential of CYP17A1 inhibitors in prostate cancer are also summarized.

show abstract

CYP17 gene polymorphisms and prostate cancer risk: A meta‐analysis based on 38 independent studies

Abstract: This meta-analysis suggests that rs743572 polymorphism is associated with PCa risk in Black population, but not in Caucasian or Asian population. Moreover, our study suggests that rs619824 and rs2486758 polymorphisms are associated with PCa risk.

Cited by 33 publications

References 41 publications

Polymorphism T→C of gene CYP17 promoter and polycystic ovary syndrome risk: A meta-analysis

Polymorphism T→C of gene CYP17 promoter and polycystic ovary syndrome risk: A meta-analysis

Effect of IL-18 gene promoter polymorphisms on prostate cancer occurrence and prognosis in Han Chinese population

The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition

Contact Info

Product

Resources

About